Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
ALERT

An Introduction to Drawdown Risk

Mutualfunds logo

PRHSX T. Rowe Price Health Sciences

  • Fund
  • PRHSX
  • Price as of: Jun 23, 2017
  • $72.04
  • - $0.07
  • - 0.10%
  • Category
  • Health & Biotech Equities

PRHSX - Profile

Vitals

  • YTD Return 21.9%
  • 3 Yr Annualized Return 12.2%
  • 5 Yr Annualized Return 21.1%
  • Net Assets $10.7 B
  • Holdings in Top 10 31.9%

52 WEEK LOW AND HIGH

$72.04
$58.23
$72.11

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.77%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 24.90%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 21.9%
  • 3 Yr Annualized Total Return 12.2%
  • 5 Yr Annualized Total Return 21.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.09%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name T. Rowe Price Health Sciences Fund
  • Fund Family Name T. Rowe Price
  • Inception Date Dec 29, 1995
  • Shares Outstanding N/A
  • Share Class No Load
  • Currency USD
  • Domiciled Country United States
  • Manager Ziad Bakri

Fund Description

The T. Rowe Price Health Sciences Fund (PRHSX) is an actively managed, specialty mutual fund covering the health and biotech sectors. PRHSX is best suited for those investors who already have core equity positions and are looking for specialty exposure.

Managers of the fund use fundamental analysis to identify the best growth candidates from within the health care sector. As such, PRHSX provides exposure to a wide range of health care-related firms, including pharmaceuticals, biotech researchers, medical device companies, health insurers/benefits managers and hospital administrators/owners. Despite its narrow focus, expenses are on the low side. The fund is internally managed by T. Rowe Price.

PRHSX - Performance

Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 21.9% -14.9% 32.6% 33.93% 2
1 Yr 9.7% -14.8% 30.4% 37.84% 2
3 Yr 12.2% * -7.5% 18.5% 9.26% 1
5 Yr 21.1% * 9.3% 21.9% 1.94% 1
10 Yr 14.6% * 6.1% 14.6% 1.01% 1

* Annualized


Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -14.2% -29.8% 2.6% 49.09% 3
2015 1.3% -20.4% 14.5% 20.91% 2
2014 17.6% -5.8% 33.7% 43.64% 3
2013 40.2% -2.6% 65.2% 49.54% 3
2012 26.4% -5.3% 36.5% 10.68% 1

Total Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 21.9% -14.9% 32.6% 34.23% 2
1 Yr 9.7% -18.3% 28.4% 29.09% 2
3 Yr 12.2% * -14.2% 18.5% 8.33% 1
5 Yr 21.1% * 9.1% 21.9% 1.94% 1
10 Yr 14.6% * 6.1% 14.6% 1.01% 1

* Annualized


Total Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -14.2% -25.1% 6.3% 52.29% 3
2015 14.4% -16.6% 39.1% 11.93% 1
2014 43.7% -5.8% 100.0% 18.35% 1
2013 100.6% -5.1% 398.7% 19.44% 1
2012 99.8% -2.6% 475.8% 8.00% 1

NAV & Total Return History

PRHSX - Holdings

Filings data as of: Mar 31, 2017

Concentration Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Assets 10.7 B 20.4 M 46.9 B 1.79% 1
Number of Holdings 128 32 355 6.25% 1
Net Assets in Top 10 3.37 B 9.25 M 20.1 B 3.57% 1
Weighting of Top 10 31.9% 19.5% 74.0% 30.36% 5

Top 10 Holdings

  1. Allergan PLC 3.15%
  2. UnitedHealth Group Inc 5.19%
  3. Cigna Corp 2.69%
  4. Humana Inc 2.68%
  5. Thermo Fisher Scientific Inc 2.64%
  6. Becton, Dickinson and Co 3.80%
  7. Alexion Pharmaceuticals Inc 2.80%
  8. Intuitive Surgical Inc 3.08%
  9. Tesaro Inc 2.71%
  10. Incyte Corp 3.20%

Asset Allocation

Weighting Category Low Category High PRHSX % Rank Quintile
Stocks
98.95% 88.73% 100.89% 11.61% 2
Cash
0.52% 0.00% 12.07% 24.11% 4
Preferred Stocks
0.36% 0.00% 0.71% 2.68% 1
Convertible Bonds
0.17% 0.00% 0.49% 1.79% 1
Other
0.00% -11.71% 2.70% 14.29% 5
Bonds
0.00% 0.00% 2.91% 4.46% 5

Stock Sector Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
Healthcare
96.34% 11.52% 99.64% 9.82% 2
Consumer Defense
1.79% 0.00% 2.14% 2.68% 1
Technology
0.65% 0.00% 64.38% 18.75% 3
Industrials
0.11% 0.00% 8.05% 8.04% 2
Utilities
0.00% 0.00% 1.11% 1.79% 5
Real Estate
0.00% 0.00% 1.50% 2.68% 5
Financial Services
0.00% 0.00% 5.16% 5.36% 5
Energy
0.00% 0.00% 0.00% 0.89% 5
Communication Services
0.00% 0.00% 0.00% 0.89% 5
Consumer Cyclical
0.00% 0.00% 5.10% 7.14% 5
Basic Materials
0.00% 0.00% 1.96% 4.46% 5

Stock Geographic Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
US
93.70% 62.83% 99.64% 7.14% 1
Non US
5.25% 0.00% 37.17% 22.32% 4

PRHSX - Expenses

Operational Fees

PRHSX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.77% 0.10% 4.31% 67.86% 1
Management Fee 0.64% 0.09% 1.25% 12.50% 2
12b-1 Fee 0.00% 0.00% 1.00% 12.66% 1
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Front Load N/A 3.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Turnover 24.90% 0.00% 699.00% 24.11% 2

PRHSX - Distributions

Dividend Yield Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Dividend Yield 0.1% 0.01% 0.94% 25.53% 2

Dividend Distribution Analysis

PRHSX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Income Ratio -0.09% -2.22% 1.40% 26.79% 2

Capital Gain Distribution Analysis

PRHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

PRHSX - Managers

Ziad Bakri

Manager

Start Date

Apr 01, 2016

Tenure

1.16

Tenure Rank

22.5%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad earned a bachelor of medical science undergraduate degree with first-class honors from the University of Nottingham and a bachelor of medicine, bachelor of surgery (M.D.) from the University of Nottingham Medical School. He also holds the Chartered Financial Analyst designation.


Tenure Analysis

Category Low

0.3

Category High

19.7

Category Average

9.02

Category Mode

0.3